Docetaxel is manufactured by Sanofi-Aventis and is used to treat cancer. ## Compulsory licenses Compulsory licenses have been issued for Docetaxel in the following instance: ### Thailand issued on January 01, 2008 [[Thailand]]'s provisions on compulsory licences can be in the Patent Act B.E. 2522 (1979). There are four main grounds for issuing a compulsory licence: - Non-working / inadequate “working” Patent not locally produced or imported, or sold at unreasonably high price relative to domestic demand. - Dependent patents Use of a later patent requiring the earlier patent’s invention. - Public non-commercial/government use For public health, environmental conservation, food/medicine shortages, etc. - National emergency / public interest Covers war, epidemics (e.g., HIV/AIDS, SARS, bird flu), national emergencies. More information can be found [here](https://www.wipo.int/wipolex/en/legislation/details/3807 ). ## Other products issued by the same manufacturer [[Docetaxel]] ## Other products for the same disease [[Erlotinib]] [[Imatinib]] [[Letrozole]] [[Sunitinib, erlotinib]] [[Gemcitabine]] [[Trastuzumab-Emtansine]] [[Pertuzumab]] [[Dasatinib]] [[Sorafenib Tosylate]] [[Sunitinib]]